References
- Kurtz D M, Tschetter L K, Allred J B, Geyer S M, Kurtin P J, Putnam W D, Jr, et al. Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51. Leukemia Lymphoma 2007; 48: 1290–1298
- Taylor C W, LeBlanc M, Fisher R I, Moore D FS, Roach R W, Elias L, et al. Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: a Southwest Oncology Group Trial. Anticancer Drugs 2000; 11: 695–700
- Rosenwald A, Wright G, Chan W C, Connors J M, Campo E, Fisher R I, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947
- Lu X, Nechushtan H, Ding F, Rosado M F, Singal R, Alizadeh A A, et al. Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas. Blood 2005; 105: 2924–2932
- Winter J N, Weller E A, Horning S J, Krajewska M, Variakojis D, Habermann T M, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006; 107: 4207–4213
- Nechushtan H, Rosenblatt J D, Lossos I S. IL-4 affects proliferation, chemosensitivity and rituximab sensitivity of germinal center B-cell like (GCB) and activated B-cell like (ABC) diffuse large B-cell lymphoma differently. ASH Ann Meeting Abs 2004; 104: 242